Table 1.
Baseline characteristics
| General characteristics | Total, n = 479 |
|---|---|
| Female, n (%) | 326 (68.1) |
| Age in years, median (sd) | 80 (6.3) |
| Major bleeding | |
| Extracranial major bleeding, n (%) | 17 (3.5) |
| Intracranial haemorrhage (ICH), n (%) | 16 (3.3) |
| Number of drugs, median (sd) | 6 (3.7) |
| Number of morbidities, median (sd) | 9 (5.0) |
| Multiple falls per year, n (%) | 430 (91.1) |
| Atrial fibrillation, n (%) | 100 (20.9) |
| Hypertension, n (%) | 312 (65.1) |
| Diabetes mellitus, n (%) | 107 (22.3) |
| Chronic Kidney Disease*, n (%) | 67 (14) |
| Heart failure, n (%) | 40 (8.4) |
| Stroke in medical history, n (%) | 97 (20.3) |
| CHA2DS2VASC, median (sd) for patients with atrial fibrillation (n = 100) | 4 (1.4) |
| HASBLED, mean (sd) for patients with atrial fibrillation (n = 100) | 3 (1.1) |
| Use of OAC, n (%) | 81 (16.9) |
| Use of APA, n (%) | 166 (34.7) |
| Geriatric features | |
| Frailty Index, mean (sd) | 0.22 (0.09) |
| Moderate Frailty, n (%) | 128 (26.7) |
| Severe Frailty, n (%) | 240 (50.0) |
| Polypharmacy**, n (%) | 337 (70.4) |
| Orthostatic hypotension, n (%) | 140 (29.2) |
| Post prandial hypotension, n (%) | 154 (32.9) |
| Parkinsonism, n (%) | 44 (9.2) |
| Gait disturbance, n (%) | 250 (52.2) |
| ADL dependence, n (%) | 104 (21.7) |
| iADL dependence, n (%) | 174 (36.3) |
| Cognitive impairment | |
| MMSE < 26 points, n (%) | 120 (25.1) |
| MoCA < 26 points, n (%) | 281 (58.7) |
| Dementia in medical history, n (%) | 24 (5.0) |
| MRI findings | |
| Number of cerebral microbleeds, mean, median (sd) | 1.8, 0 (6.9) |
| Presence of cerebral microbleeds, n (%) | 169 (35.8) |
| Presence of lacunes, n (%) | 115 (24.1) |
| Fazekas score, mean (sd) | 1.8 (0.9) |
| Fazekas score ≥ 2, n (%) | 253 (52.9) |
| Macro infarction, n (%) | 42 (8.8) |
| MTA score, mean (sd) | 2.0 (1.5) |
| Relevant MTA, n (%) | 281 (58.8) |
| Global atrophy, mean (sd) | 1.4 (0.8) |
Abbreviations: OAC oral anticoagulation, APA antiplatelet agents, ADL activities of daily living, iADL instrumental activities of daily living, MMSE Mini Mental State Examination, MoCA Montreal Cognitive Assessment, MTA mesotemporal atrophy.